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Abstract 
Adaptive capability describes the ability to respond to external shocks and take advantage of 
new opportunities. Central to this is path dependency and the scope for turning historic 
strengths to new purposes. This paper explores the emergence of a nascent bioscience cluster 
in Nottingham. A novel analytical device based on Kingdon’s multiple streams framework is 
applied to explore the emergence of a new development path in this city. Local actors used a 
window of opportunity created by contingencies at the level of industries, firms and place to 
create a development path mobilizing legacy assets including physical and human capital. 
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Adaptive Capability and Path Creation in the Post-industrial City: The Case of 
Nottingham’s Biotechnology Sector 
 
 
Introduction 
Just how new development paths are created in city-regions especially those that are or have 
been home to declining industries has been described as one of the most, ‘intriguing and 
challenging questions’ (Neffke et al., 2011, 241). Research in this field has begun to identify 
some of the causal factors, mechanisms (Dawley, 2013), agents (Simmie, 2012) and conditions 
(Fornahl et al., 2012) involved. However despite this, a recent study (Dawley et al., 2015, 257) 
noted that, ‘more theoretically informed and empirically grounded research’ is required in order 
to provide greater clarity on new path creation. 
 
This study aims to contribute to filling this gap in our knowledge through the application of a 
modified version of Kingdon’s (1995) multiple streams framework (MSF) in order to analyse 
the path creation phase of Martin’s (2010) path dependency model of local industrial evolution 
(see figure1).  This is the phase where according to Martin (2010, 21), ‘experimentation and 
competition among local agents leads to the emergence of a new path’. Through the application 
of this framework we seek to provide insights into the process by which new paths are created. 
Like Kingdom’s framework our version comprises three streams of activity. However our 
streams reflect differing scales of activity, starting with markets/industries at the highest level, 
followed by firms and then institutions. Co-evolution of these streams over time leads to their 
converging, thereby creating a ‘window of opportunity’. It is at this point according to Kingdon 
(1995, 20) that ‘policy entrepreneurs’ whom he describes as people capable of ‘coupling 
solutions to problems’, emerge to put forward potential solutions.  We prefer the term enablers 
but their function is the same, they are local agents (i.e. individual and corporate actors) able 
to make use of this window in order to effect change. In this instance the change is the 
launching of a new industrial development path, one involving the re-tasking of physical assets 
and the mobilisation of local knowledge and skills accumulated in the city-region over many 
years.  
*********************** 
Insert Figure 1 
*********************** 
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We apply this conceptual model to an in-depth case study exploring the emergence of a nascent 
bioscience based industrial cluster in the city of Nottingham in the UK. The development of  
BioCity Nottingham, home to a large and growing concentration of biotechnology and 
healthcare companies, has come to symbolise Nottingham’s economic reinvention as a 
‘knowledge economy’ following years of de-industrialisation. From its roots deep in the 
manufacturing dominated local economy that spawned ‘Saturday Night and Sunday Morning’1, 
we chart the rise of exactly the kind of knowledge intensive industrial cluster that has been an 
object of desire for national, regional and local policy makers since the Millennium and before 
(Swords, 2013). Interesting though the BioCity incubator’s emergence is in its own right, the 
principal focus of this paper is on what this case can tell us about the continuing evolution of 
Nottingham’s economy and the implications that this may have for our understanding of 
regional economic path creation and adaptive capability more generally. 
 
The local economy of Nottingham faced major structural changes in the late 1990s as 
manufacturing employment contracted and the balance of the local economy shifted towards 
services. The case places particular emphasis on the contribution of firms, the restructuring of 
industry sectors and institutional changes that occurred at this time, to the city’s adaptive 
capability. In the process the case study reveals a notable example of adaptation as the local 
economy moved away from a previous path of regional and sectoral development, towards a 
new and yet related trajectory. Central to this process was the purposive re-tasking of physical 
assets and the mobilization of knowledge assets that were the legacy of one of the city’s historic 
industrial strengths. 
 
The city’s industrial past provided a potential escape route from ‘negative lock-in’ (Amison 
and Bailey, 2015, 397) for a city on a declining development path caused by a steady process 
of de-industrialisation since the 1970s. Nottingham’s emerging bioscience cluster may be an 
example of what Christopherson (2009, 277) terms, ‘phoenix industries’.  Not only has a new 
industrial sector arisen out of an old one, a small number of dominant large employers have 
been replaced by many small and medium sized companies. The case study provides a valuable 
insight into the messy and unpredictable process that local agents have to navigate, offering a 
glimpse of why some localities may be more successful in enabling this process than others. 
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The paper concludes by considering the wider relevance and applicability of this model of 
bioscience based regional development. In so doing it endeavours to isolate those factors that 
are ‘place specific’ from those that have wider applicability. 
 
Selective Literature Review 
Evolutionary accounts of regional and local economic development are not new. Alfred 
Marshall (1920) originated the concept of the industrial district and sought to explain the 
emergence industrial clusters with reference to a range of factors such as proximity to natural 
resources and markets for goods and labour. More recently, Nelson and Winter’s (1982) 
seminal work on evolutionary economics explored the role of economic actors and paths of 
change in the context of time and space. Recent years have seen a marked resurgence of interest 
in evolutionary accounts of regional and local economic development – often associated with 
the New Economic Geography or the ‘evolutionary turn in economic geography’ (see for 
example Boschma, 2004, Martin and Sunley, 2006). Central to these perspectives on economic 
development are the related concepts of path dependency, lock-in and adaptive capability.  
Path dependency is a term that finds application in both economic geography and institutional 
perspectives in political science. It highlights the manner in which a region’s future paths of 
development are constrained by the products of social and economic history: accumulations of 
capital (human and physical), concentrations of expertise, productive infrastructure, 
institutional architecture etc. There remains scope for agency, but it is constrained by the 
products of history and the resources that represent a legacy of prior development. 
Closely associated with the concept of path dependency is the idea of lock-in – the manner in 
which a locality or region gets trapped on a path of relative or absolute decline. Often this is 
associated with the demise of a key local industry. Prior to the millennium, Nottingham bore 
all the hallmarks of a city region trapped on just such a trajectory. Martin and Sunley (2006, 
430) note that, 
“place dependence is an important dimension of path dependence. This implies that 
forms of co-evolution in which there are mutually constitutive interactions and 
feedbacks between firms and other institutions are to some degree place-specific, and 
that these interactions occur simultaneously across several different scales.”  
The literature devotes far less attention to the means through which lock-in may be avoided. 
From a policy perspective, this is perhaps the critical question. One response to this has been 
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to focus on the factors that influence a region’s adaptive capability (Martin 2005). Adaptive 
capability refers to the ability of a region to respond to shocks and take advantage of new 
development opportunities from wherever they appear. Central to this attribute is the ability to 
apply historic accumulations of assets or capabilities to new and emerging opportunities as and 
when they arise.  
More recently there has been widespread recognition of the need to engage more fully with the 
process of path creation (Martin and Sunley 2006).  This was a theme to which Martin returned 
in his Roepke Lecture of 2010, providing a critique of the path dependency model and the 
central concept of lock-in as privileging continuity over change (Martin, 2010). This may be 
seen as a reaction against the perceived historical determinism implied by many formulations 
of path dependency. Martin’s response was to argue for a more evolutionary account – applying 
institutionalist insights from political science to the study of economic geography. 
Recent papers by Doussard and Schrock (2015) and Dawley et al (2015) and Bristow and Healy 
(2015) respond to this challenge. The former’s study of North American manufacturing 
highlights the importance of firm, technological, place and market level contingencies 
structuring uneven spatial development. In contrast, Dawley at al (2015) identify regional 
policy initiatives and the multi-scalar state as fulfilling mediating functions in the creation of 
new paths of development. Bristow and Healy (2015) in turn explore the nature and scope of 
agency in regional development. Arguably the key insight that they derive is a recognition of 
the importance of interaction between actors and the sense in which “agents are co-evolving, 
constantly adapting to each other and to their environment” (Bristow and Healy 2015, 246). 
This paper engages with the process of path creation – with a particular emphasis on the 
interaction between institutions, agents and place over time. We seek to identify the sources of 
a city region’s adaptive capability in the co-evolution of institutions, firms and markets. A 
simplified model of path creation is used that takes inspiration from the multiple streams 
framework (MSF) of John Kingdon (1995). MSF is a perspective on the policy process as 
comprising three parallel streams of activity: problems, policy and politics. Convergence 
provide ‘windows of opportunity’ to effect changes of policy direction. The agency of 
particular ‘policy entrepreneurs’ is seen to be critical if opportunities are to be realised. 
The appeal of MSF as a model of the policy process is that it eschews simplistic linear or 
cyclical representations of the process (Rossiter and Price 2013). The strength of this approach 
is its ability to disentangle the often messy process that is the ‘real world’ of policy. A world 
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in which parallel streams of activity happen simultaneously, sometimes independent of each 
other, sometimes interacting. These characteristics make the MSF account of policy change an 
interesting and relevant analogue for similar processes at work in regional and local economic 
path creation. Central is a recognition of the importance of agency if policy outcomes are to be 
understood. Following Dawley et al (2015) and Bristow and Healy (2015) we see agency 
associated with the local implementation of regional policy as an important ingredient in the 
local ‘recipe’ that led to the creation of Nottingham’s growing biotechnology sector. 
 
Methodology 
In developing a case study of the development of the local economy in Nottingham, multiple 
sources of data were employed.  Extensive use was made of documentary and archival 
materials. The documentary materials included a variety of items from weekly and monthly 
trade magazines and periodicals, as well as the local and financial press. A number of business 
histories, industry studies and even biographies and autobiographies were also used to provide 
background data on the local economy and the development of the pharmaceutical industry in 
the region. Overall these sources provided a wealth of valuable background and technical 
information in relation to the pharmaceutical industry in Nottingham.  The study also drew on 
previous research carried out by the authors exploring the nature of the BioCity incubator and 
analysing its growth and development, as well as other studies of the biotechnology incubator 
sector in the UK. The data gathered in this way was complemented by a small number of 
interviews with ‘key informants’ (John and Reve, 1982), including staff employed at the 
facility prior to its closure as an industrial research laboratory, at some of the agencies involved 
in negotiating and organising the transition to an incubator and at the incubator itself. Data 
from the interviews was extremely helpful in understanding and making sense of some of 
technical aspects surrounding the activities undertaken at the laboratory facility and the key 
issues that arose in facilitating the transition. 
 
Case Study: A new development path emerges in Nottingham 
Adaptive capability and the development of Nottingham’s economy 
Nottingham has long been a centre of governmental, commercial and cultural life (Heath, 
2010). The establishment of the hosiery industry at the start of the eighteenth century saw the 
town emerge as a major centre of manufacturing industry (Henstock, Dunster & Wallwork, 
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2006). The physical legacy of this industrial heritage is still apparent in the Lace Market area 
today.   
New industries like cycle manufacture, tobacco and pharmaceuticals, took root in the late 
nineteenth and early twentieth centuries. Although in one case, that of the cycle maker Raleigh, 
founded by two textile machinery makers and a lace worker (Rosen, 2002), this was the product 
of a process of industrial adaptation that was to re-occur as the local economy evolved. Boots 
began the development of the city’s industrial science base when the outbreak of war with 
Germany in 1914 brought crippling shortages of synthetic pharmaceuticals (Corley, 2003). 
Jesse Boot launched a range of pharmaceutical products extending from aspirin to anaesthetics 
(Corley, 2003). 
The interwar years were marked by further adaptation as hosiery and knitwear (Chapman, 
2002) largely replaced lace (Wells, 1966). New industries (Wells, 1966), continued to expand 
and grow, as the economic environment of the interwar years favoured branded consumer 
goods for the home market (Pollard,1992). Boots continued to expand pharmaceutical 
manufacture. The company had the third highest level of patent filings for a UK-owned 
pharmaceutical company (Slinn, 2008) by the late 1930s. Overall the period saw a significant 
re-shaping and diversification of employment in the city (Wells, 1966).  
By the 1960s Boots, Raleigh and Players had become mainstays of the local economy 
(Chapman, 2006), with each employing almost 10,000 in the city. Boots had developed into 
one of the UK’s leading pharmaceutical companies, having invested heavily in new research 
facilities. Among its major achievements was the discovery of the widely used pain-killer 
ibuprofen.  However Nottingham reached its zenith as an industrial city in the 1960s (Heath, 
2010). Increased car ownership combined with stiffer overseas competition saw Raleigh’s 
output and employment steadily decline (Chapman, 2006). Likewise Players, now part of 
Imperial Tobacco, was subject to a similar pattern of declining employment during the course 
of the 1970s and 1980s, in the face of increasing public recognition of the health risks 
associated with tobacco and cigarette smoking.  
************ 
Insert Table 1 
************ 
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While Raleigh and Players went into decline from the 1970s Boots continued to prosper. It 
acquired Crookes Laboratories and Rucker Pharmacol, and in the 1980s the Flint division of 
Baxter Tavernol (Chapman, 2006) - an American concern whose drug synthroid, was a big 
selling treatment for thyroid conditions. Boots was the UK’s fifth largest pharmaceutical 
manufacturer by the mid-1980s (see table 1), but lacked the international marketing capability 
of larger rivals.  
 
By the early 2000s both Raleigh and Players had ceased manufacturing operations and 
manufacturing employment in city continued to contract. This decline was matched by the 
growth of service sector employment. This transformation has seen particular growth in the 
business/information services with several large companies now based in Nottingham 
including Experian, Capital One and Ikano. Experian is much the largest with more than 2000 
employees in the city (Lawton et al., 2014, Nottingham Post, 2013). Unlike the other two which 
are the result of inward investment, Experian originated in Nottingham, having begun life in 
the 1970s as the credit checking arm of Great Universal Stores (Nottingham Post 2013). Thus 
the overall trajectory that has led Nottingham to become dominated by the service sector, 
reflects an interesting mix of capabilities that are the product of successive evolutions of firms 
and industries. In this respect Nottingham differs markedly from near neighbour Derby. The 
recent development trajectories of Nottingham and Derby have been contrasted in the 
following terms:  
“…over recent decades Derby and Nottingham have assumed quite different roles in 
the space-economy of the Region. The former can be characterised as the regional 
centre for manufacturing (with a particular emphasis on transport), while the latter has 
assumed the role of the regional centre for business, financial, health and education 
services” (Rossiter 2016; 842) 
Viewing the East Midlands region from a wider spatial perspective, Coombes et al. (2005) 
highlight the ‘pre-eminence’ of Nottingham as a regional centre, while hesitating to ascribe to 
it the dominance characteristic of cities like Birmingham and Manchester in the West Midlands 
and North West respectively. The continuing significance of the cities of Derby and Leicester 
in the space-economy of the region they attribute to the distinctive pattern of industrialisation 
in the East Midlands. A pattern that saw each of the five historic county towns grow without 
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any one totally subsuming or dominating the others in the manner seen in some English regions 
(Beckett, 1988, Coombes et al., 2005).   
A new development path 
In the last couple of decades a new development path, has emerged in Nottingham. Based on 
bioscience and health, the most obvious symbol of this new development path is the bioscience 
cluster centred on the BioCity incubator and comprising more than 60 bioscience related 
companies established in Nottingham since 2000. Other symbols include Nottingham’s 
designation by the UK government in 2005 as one of six ‘Science Cities’ (Charles and Wray, 
2015), and the East Midlands Development Agency (EMDA)’s selection in its Regional 
Economic Strategy, entitled ‘A flourishing region’ (EMDA, 2006), of bioscience/health as one 
of four priority sectors predicted to, ‘make the greatest contribution to the East Midlands 
economy over the lifetime of the strategy’. Similarly the Nottingham Growth Plan (Nottingham 
City Council, 2012), explicitly recognized recent changes in the city’s economy by identifying 
biosciences as a ‘growth sector’ in which the city had a ‘competitive advantage’.  
 
Although modest in scale by the standards of bioscience concentrations in the traditional 
heartlands of London and the South East (Smith and Ehret, 2013), the emergence of bioscience 
in Nottingham is significant for a non-core region. This momentum has been sustained over a 
15 year timeframe and shows no signs of slowing. How has this come about? It is tempting to 
suggest that it is simply a matter of serendipity - a product of a series of chance events such as 
BASF’s decision to sell its pharmaceutical division to Abbott Laboratories in 2000 and the 
gifting of the Nottingham site to Nottingham Trent University (NTU). This would be simplistic 
and ignores strong elements of path dependency revealed when we consider the wider 
economic and institutional context. 
 
The Multiple Streams Framework 
Using the modified version of Kingdon’s (1995) MSF there appear in this case to be three 
parallel yet inter-acting and co-evolving streams of development  (see figure 2). These came 
together to create a ‘window of opportunity’ for Nottingham at the beginning of the twenty-
first century. These streams also interacted to provide the capability necessary to take 
advantage of an opportunity that they were implicated in creating. 
 
*************** 
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The market/industry stream 
The first stream of activity operates at the market/industry level. The 1990s were a tumultuous 
decade for the worldwide pharmaceutical industry, with a succession of high profile mergers 
(see table 2), including several of which were cross border ones. This brought significant re-
structuring of the industry (Owen, 1999) as consolidation led to the emergence of a small 
number of pharmaceutical giants. 
 
Underlying this process were a number of factors. Foremost was the rising cost of drug 
development, with leading firms spending 15-18 per cent of their turnover on research and 
development (R & D), and a new drug taking at least 10 years to develop at a cost of $250-
$350 to develop (Collett, 2000). Consequently a major driving force for increased 
consolidation in the industry was to economize on R & D (Jones, 2000). 
 
************ 
Insert Table 2 
************ 
 
Changes occurred in the model of R & D used by many pharmaceutical companies. There was 
a gradual move away from ‘the traditional paradigm of R & D’ (Chesborough, 2006) associated 
with closed models of innovation found in vertically integrated firms. With greater emphasis 
on  biotechnology (Pisano, 2006), the use of combinatorial chemistry and microassays, 
pharmaceutical companies, in a manner similar to firms in other high tech sectors, such as 
computer firms in Silicon Valley2 (Saxenian, 1996), were able to utilize outsourcing. Through 
outsourcing they came increasingly to rely on external R & D. Between 1993 and 1998 external 
R & D undertaken by pharmaceutical firms in the UK more than doubled to £555m (Jones, 
2000: 349). Third party organisations became the source of a range of research services and 
even new drugs. Across the UK the number of small specialist biotechnology companies 
doubled between 1994 and 1999 (DTI, 1999). The shift away from a ‘closed’ model of 
innovation in favour of  more ‘open’ models created a market opportunity for exactly the kinds 
of biotech firms that would later come to occupy BioCity, as did the emergence and adoption 
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during the 1990s of the ‘triple helix’ model (Etzkowitz, 1993) of university-industry-
government collaboration. 
 
 
The firm stream 
The second stream operates at the firm level and in this case centred on Boots and its 
pharmaceutical division. This stream is influenced to a significant extent by the industry/market 
developments described above in that Boots was responding to the changing nature of its 
competitive environment and the wider restructuring that was happening throughout the sector. 
By the 1990s Boots had a potentially valuable drug development pipeline. Its most notable 
success had been the discovery of the painkiller ibuprofen, but there were others including 
synthroid and sibutramine, though the company’s lack of international marketing skills, meant 
none quite realised their full potential as a blockbuster drug. Then a combination of regulatory 
problems, together with leadership changes that brought in a strong retail focus resulting in a 
series of costly acquisitions (these included the Halfords automotive parts chain, and the 
Payless and FADS home improvement chains), began to call the future of the company’s 
pharmaceutical division into question. 
 
As part of the company’s new focus the over-the-counter (OTC) and contract manufacturing 
units were split off. Boots Pharmaceuticals retained responsibility for prescription only drugs. 
This was the point at which the company’s drug pipeline hit problems. In 1992, having spent 
14 years and £150 million on research and development (Hoskings, 1993), Boots was finally 
granted a licence in the UK for its new heart drug manoplax (see table 3). Back in 1979 
biochemists at Boots laboratories in Nottingham first synthesized flosequinan, the active 
ingredient in manoplax, and it came to be seen as the, “great white hope not only for Boots 
Pharmaceuticals, but for the wider group” (Hoskings, 1993). Within a year, Boots was forced 
to withdraw manoplax, as a result of regulatory concerns linked to new research which showed 
that while it was effective in relieving the symptoms of congestive heart failure (CHF) it could 
shorten life slightly (Rossiter and Smith, 2017).  
 
************ 
Insert Table 3 
************ 
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With its ambitious plans for expansion into new areas of retailing having failed and its drug 
development pipeline in tatters, Boots took the decision to divest itself of the prescription only 
drug business. Early in 1995 it was sold to the German chemical conglomerate BASF for £850 
million (Green, 1994).  Although this ended Boots involvement in the prescription drugs sector 
the company retained the over-the-counter pharmaceutical business along with contract 
manufacturing. 
 
Part of the attraction for BASF was that it already had a pharmaceutical business which traded 
under the Knoll brand and a worldwide marketing network. Also Boots had an anti-obesity 
drug, “at a fairly advanced stage” (Hoskings, 1993), and this held the promise of large sales in 
the US where BASF already had a significant presence. Despite these attractions BASF’s 
ownership of the Boots research laboratories in Nottingham was to prove relatively short-lived.  
 
Within four years, BASF too was conducting a strategic review. The pharmaceutical division 
was still relatively small comprising just one tenth of overall group turnover (Abelhauser et al., 
2004) and many found it difficult to see BASF as anything other than a chemical company. 
This was compounded by regulatory concerns limiting the use of reductil the anti-obesity drug 
developed by Boots (Rossiter and Smith, 2017). With a wave of mergers driving many 
pharmaceutical companies to seek further acquisitions, BASF took the decision to divest. In 
March 2001, following approval from the European and US competition authorities, Abbott 
Laboratories of Illinois acquired the worldwide business of Knoll Pharmaceuticals for $6.9 
billion (Abelhauser et al., 2004). This time the purchaser wanted the intellectual property but 
not the Nottingham site or its staff. Consequently BASF was forced to make 450 highly 
qualified scientific staff redundant. The redundancies coincided with the closure of the last 
Raleigh manufacturing plant in Nottingham and another big manufacturing plant in the city, 
Royal Ordnance owned by British Aerospace.  
 
The institutional stream 
The third stream comprises the development of local institutions, including both scientific and 
administrative organisations. This was to prove critical in developing the adaptive capability 
necessary to take advantage of a window of opportunity when it arose. There is a strong sense 
in which these institution were themselves a product of a particular industrial milieu and the 
constellation of local firms within which Boots was a prominent member. Chief among these 
public sector anchor institutions to develop was the Queens Medical Centre (QMC) opened in 
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1977 following the creation of a new Medical School at the University of Nottingham in 1970. 
The QMC was the first purpose-built teaching hospital to be constructed in the UK, and is now 
one of the largest teaching hospitals in England (Mathieson, 2011). Currently the main acute 
hospital for the East Midlands region QMC employs nearly 12,000 staff. As such it constitutes 
a significant addition to the City’s science base, helping to generate ‘critical mass’ in health 
related biosciences (Rossiter and Smith, 2017). It thus fulfils a dual role: boosting the local 
science-based labour market in and stimulating demand for health related bioscience services 
and expertise. 
 
Other important public sector anchor institutions that form part of the city’s science base 
included its two universities. From their earliest years both had close contact with local 
industry.  Nottingham’s University College finally gained its charter to become a full university 
in 1948 having acquired a large new 300 acre campus two miles south west of the city in the 
interwar years, through the generosity of Boots founder (Chapman, 1974).  From this point 
onwards Nottingham University developed into one of the UK’s leading research intensive 
universities, with major departments in bioscience and healthcare and rated a, ‘leading 
biotechnology research university’ in terms of funding support from the relevant UK research 
councils.  A measure of the university’s rise among the scientific community was its first Nobel 
prize in 2003 awarded to Sir Peter Mansfield for his work on Magnetic Resonance Imaging 
(Ehret et al., 2012). The city’s polytechnic meanwhile, which had for a long time played an 
important role in training technicians and laboratory staff working in local companies like 
Boots, merged with the city’s college of education in 1975.  It gained independence from local 
authority control following the 1988 Education Act, before achieving university status in 1992 
when it became Nottingham Trent University (NTU). 
 
The development of Nottingham’s two universities and their relation to local industry is itself 
noteworthy and provides further evidence of co-evolution. Indeed, in different ways the 
development of both universities may be seen as directly stimulated by local industry. The 
philanthropy of Jesse Boot played a key role in the development of the University of 
Nottingham, just as the needs of local manufacturing firms had stimulated the creation of 
NTU’s earliest antecedent – the College of Design - in the 1840s. To this extent both 
universities can be regarded as products of a particular industrial milieu.  
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Other important institutional developments locally included the award of unitary status to 
Nottingham City Council in 1998. The significance of this was to increase the authority’s 
influence over and resources devoted to strategic planning, transport and economic 
development in the city. The following year saw another important institutional development, 
the establishment of regional development agencies (RDAs) across the UK, as part of New 
Labour’s new focus on regional policy3. This included the East Midlands Development Agency 
(EMDA) based in Nottingham. EMDA was a key part of the actor network associated with 
attempts to implement the government’s cluster policies derived from the work of Michael 
Porter, that were very much in vogue at this time (Swords, 2013). EMDA was also an important 
actor in economic development at the local level. This derived both from its statutory remit and 
the funds at its disposal. By accident of location, it is noteworthy that EMDA’s main offices in 
Nottingham overlooked the Pennyfoot Street laboratory site – meaning that the site and its 
potential future use could hardly fail to be prominent in the minds of key EMDA staff. 
A Window of Opportunity 
The convergence of these three streams in the late 1990s served to create both a major economic 
challenge and a means to respond. In the industry stream, firm consolidation combined with 
increased use of open innovation and increased commercialisation of university research 
through the triple helix model, caused many in the pharmaceutical industry to question the 
value of large centralised research laboratories. In parallel at the firm level, Nottingham saw 
the departure of two of its big three employers (Raleigh and Players). Then first Boots and then 
BASF ran into major problems with their drug development pipelines, bringing the future of 
the city’s pharmaceuticals manufacturing and research into question. Meanwhile the 
institutional stream had seen further development as the incoming Labour administration of 
1997 began to implement new regional and cluster policies leading to the creation of a 
development agency based in Nottingham.  
 
It was the decision by BASF to sell the Knoll Pharmaceuticals business to Abbott Laboratories 
in 2000 (Abelhauser et al., 2004) in a deal that involved the intellectual property (i.e. the drugs 
and drug pipelines) but not the Nottingham site and its staff that proved to be a critical juncture. 
BASF had little choice but to close the facility and make nearly 500 staff redundant. This 
directed attention to the wider problem of the decline Nottingham’s industrial base. Hence the 
sale to Abbott Laboratories proved to be what Zahariadis (2007, 72) terms a ‘focusing event’, 
serving to couple the three streams together at a critical moment in time, and creating a 
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‘window of opportunity’. This created a fertile environment for various actors in Kingdon’s 
(1995, 165) words, “to push their pet solutions”.  
 
A number of potential solutions to the problem of what to do with the former Boots research 
laboratories, were to emerge from a variety of actors able to play the part of Kingdon’s (1995, 
179) ‘policy entrepreneur’. The most obvious solution was for BASF as the principal actor, to 
find another pharmaceutical manufacturer or a firm working in a similar field, to purchase the 
facility. But as one former employee noted, “nobody wanted the site when we tried to sell it for 
its existing purpose – that was clear”. Hence despite the company’s best efforts it very quickly 
became apparent that this was not a viable option. A second solution also involved BASF as 
actor. This involved demolishing the buildings, cleaning up the site and selling it to a developer 
able to put the site to an alternative use. However this proved not to be a feasible option because 
much of the land was badly contaminated through earlier industrial activity meaning that, as 
the source quoted earlier noted,  
“it would not be worth anything particularly as its riddled with tributaries of the river 
Lean underneath, which means building anything on top of it as a property development 
was also going to be monstrously expensive”.  
 
Given this apparent impasse, a third solution to come forward involved a different actor. Given 
the site’s proximity to NTU’s city campus in the heart of Nottingham, the possibility of the 
university taking it over was considered. Talks were held with Ray Cowell, NTU’s vice-
chancellor at this time. A number of visits by university staff to look at the Pennyfoot Street 
laboratories were undertaken. Having envisaged that they would be able to convert much of 
the space to lecture theatres and classrooms in order to provide space for teaching, they were 
disappointed to learn that this would not be possible. Two factors lay behind this. In part BASF 
wasn’t keen on wholesale conversion, but more significant was the fact that to fund the changes 
NTU would have needed help from EMDA. Wherever possible, EMDA’s senior management 
tried to avoid being seen to favour a single institution where others in the same sector could be 
disadvantaged.  It is also doubtful whether a teaching only use would have been seen as 
sufficiently close to the agency’s strategic priorities to justify funding. As a result this third 
option was, “pretty soon squashed”. By this stage a fourth possible solution involving another 
group of actors had emerged.  
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When the closure of the site was announced several of BASF’s employees, including senior 
scientific staff, began making plans to establish spin-off businesses utilizing their prior 
expertise and experience. The furthest advanced were a team of specialists in obesity 
treatments, who set up a company called RenaSci Ltd, providing “contract screening and 
expert services”. They had been allowed to remain on site and were keen to rent laboratory 
space. Nor were they the only ones keen to rent space. A Cambridge based company was also 
very keen to rent specialist chemistry laboratory space. Hence a fourth possible solution to 
emerge in this window of opportunity was the idea that the redundant research laboratories 
might be turned into some form of incubator housing small start-up bioscience businesses.  
 
In the event this was the solution that won the day. It led to BASF announcing in August 2001 
that it was gifting the laboratories in Nottingham to NTU. Valued at some £4 million the facility 
comprised more than 100,000 square feet (THE, 2001) of laboratory space. The laboratories 
would have cost close to £50 million to build and equip at then current prices (Hansard, 2008). 
It was the largest corporate donation ever to have been made to a post-1992 university 
(Hansard, 2008).  
 
However it required a ‘policy entrepreneur’ to enable this solution to gain traction. This was 
the newly formed development agency, EMDA. The agency was in a unique position. Created 
in 1999, it was very much a ‘new kid on the block’. Despite this, or more likely because of it, 
EMDA was eventually able to broker a deal.  Central to this deal was ensuring that the city’s 
two universities, who often found themselves in competition both for students and academic 
staff, worked together.  
 
EMDA’s distinctive contribution to the local recipe was to facilitate the establishment of a 
collaborative joint venture comprising the two universities and EMDA. The Agency also had 
a remit from the then Department for Trade and Industry to implement regional cluster policies 
and to this the Agency could therefore add a level of financial resources commensurate with 
the task of re-purposing the Pennyfoot Street laboratories. 
The result was what has been described as, 
“a unique example of strong collaboration between a Regional Development Agency 
(East Midlands Development Agency), two universities (the Nottingham Trent 
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University and the University of Nottingham) and a major science–based company 
(BASF plc).” (Hansard, 2008). 
This collaboration involved the laboratories, though now owned by NTU, being operated by a 
joint venture involving a three way partnership between NTU, Nottingham University and 
EMDA. The laboratories were to be used as an incubator housing small start-up firms not only 
in biotechnology but also in healthcare, including several that employed former BASF/Boots 
and others founded by staff from both of the local universities.  In return BASF agreed to cover 
the cost of running the facility until the partners had had an opportunity to, “develop a robust 
business plan and secure the necessary funding” (Hansard, 2008), and the  new operating 
company was ready to take it over. 
 
The BioCity incubator and the development of Nottingham’s bioscience cluster 
Thus was borne ‘BioCity Nottingham’ a bioscience incubator designed to facilitate the 
biomedical research of universities in the region, especially at the technology-transfer stage. 
The first phase of the development was opened by the science minister, Lord Sainsbury in 
September 2003 (Connon, 2003). By 2009 two further phases had been opened (Smith and 
Ehret, 2013). In 2014 plans were announced for the construction of an entirely new building. 
Due to open in 2017 this new facility will provide a further 50,000 square feet of laboratory 
space. This latest addition will consolidate BioCity’s position as by far the largest bioscience 
incubator in the UK (McDonald-Junor 2016). 
 
The mix of tenants reflects that found in other non-core regions. Just over one third of the 
science-based companies, were utilising a ‘product’ (i.e. drug discovery) business model, based 
on what Pisano (2006, 2) terms a model designed to, “monetize intellectual property” (IP). In 
contrast, the other two thirds were using a ‘service’ business model. With this business model 
companies are not seeking to commercialise intellectual property but instead were contract 
research organisations (CROs) focusing on the provision of a range of specialised research 
services that typically facilitate the new product development process of third parties (Kasabov 
and Delbridge, 2008). McDonald-Junor (2015) finds a similar pattern evident in peripheral 
regions within the UK that are home to concentrations of bioscience related firms. 
 
What emerges is a picture of a successful biotech incubator that formed the basis of an 
embryonic bioscience cluster in Nottingham – centred on but not limited to BioCity. Hence 
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when BASF took the decision to sell Knoll Pharmaceuticals to Abbott Laboratories in 2000, 
all three of the streams in figure 2 converged. By so doing they created what was potentially a 
unique window of opportunity. Had the site become available ten years earlier or ten years later 
it is much less certain that local institutions would have had the capability or resources required 
to take advantage of the opportunity. Through these three co-evolving streams a new window 
of opportunity emerged alongside the institutional capability to take advantage of it.  
 
Similar path creation elsewhere? 
The case of Nottingham and the manner in which a new bioscience development path has been 
created in this way raises a number of important questions. For policymakers and those 
involved in economic development perhaps the crucial question is whether this model is place 
specific or is capable of wider replication?  
Recent evidence indicates the latter, with clear signs that the Nottingham recipe is transferable 
and has been applied at other locations in the UK in what amount to similar situations. In each 
instance the trigger for the development of a bioscience incubator has been the departure (or 
significant down-sizing) of a major pharmaceutical company and the associated closure of a 
major research laboratory facility. Table 4 provides details of three notable examples, namely 
BioPark Herts developed at laboratories vacated by the Swiss pharmaceutical giant Roche, 
BioCity Scotland at Motherwell developed from laboratories vacated by the American 
pharmaceutical company Merck and BioHub Manchester utilizing the laboratories of the 
British pharmaceutical company Astra Zeneca. All three were triggered by the 
departure/closure of research facilities and like BioCity Nottingham comprise refurbished 
research laboratories rather than new build facilities as often found elsewhere. This should be 
no surprise given the character of the concentration, intensification of competition and the shift 
to ‘open innovation’ that marked the global pharmaceuticals sector in the opening decades of 
the twenty-first century. This was a global phenomenon that impacted on many firms and the 
localities in which they were based. 
************************** 
Insert Table 4 
************************** 
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The similarities go beyond the simple reuse of vacated laboratory space. In each case, we can 
observe the redundancy of a long established industrial facility. It is evident from these 
developments that many of the ingredients central to the Nottingham bioscience story are 
present in other localities. Furthermore, in the explicit use and acknowledgement of the BioCity 
Nottingham model, we see evidence of policy transference/learning between agencies and 
authorities in different UK localities.  A local National Health Service (NHS) influence is 
significant in two of the four sites in question and economic development/enterprise agencies 
were significant players in three. Local authorities also played significant roles – particularly 
in the period after 2010 when the English RDAs were abolished. 
Equally, it is possible to identify at least one example of a similar laboratory facility proving  
more problematic to re-task or re-use. The case of the former Astra Zeneca facility in 
Loughborough is instructive – not least because closure coincided almost exactly with the 
abolition of EMDA, one of the key institutional actors central to the development of BioCity 
(Mathiason 2010). Occurring a full decade after BioCity, but in the same region and in a town 
that is also home to a university with a relevant research profile, some but not all components 
of Nottingham’s local recipe were present. At the time of writing, more than seven years after 
closure was announced, much of the site remains unused4.  
 
Concluding Discussion – of agency and agencies 
It is at the firm and the institutional levels that we start to see the emergence of a more place 
specific set of contingencies that, with the considerable benefit of hindsight, we can say led to 
the creation of a unique window of opportunity in Nottingham circa 2000/2001. It is here too 
that we see the evolution, in the interplay between firms, administrative and scientific 
institutions, of the capabilities necessary to take advantage of the opportunity. We also observe 
the emergence of specialised and localised markets for scientific labour and services of direct 
relevance to the kinds of biotech businesses attracted to Nottingham and BioCity after 2001. 
Equally important is the role of agency – individual, corporate and institutional. From the gift 
of a fully equipped industrial laboratory and trial drug manufacturing facility by BASF – to 
key decisions by individuals, company boards and institutions, agency shaped both the 
problems faced by Nottingham (losing pharmaceuticals manufacture) and the availability of 
specific assets that could be redeployed to take advantage of a new local and global opportunity.  
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Finally we note the key role played by a new institutional player on the ground in Nottingham, 
with both the remit and the resources to act as an enabler or in Kingdon’s (1995), terminology 
‘a policy entrepreneur’ able to couple the three different streams of our version of the MSF in 
order to establish a new development path in the city.  A path that was rooted in Nottingham’s 
history of industrial science and centred on the former Boots laboratory in Pennyfoot Street. 
Thus while Nottingham’s recent development carries a strong flavour of path dependency, it is 
impossible to fashion a plausible explanation for the emergence of a bioscience related 
development path in recent years without acknowledging the important role fulfilled by both 
individual and institutional actors. Indeed, this may be the most noteworthy insight can be 
derived from this case for wider debates about the nature of path creation in post-industrial 
cities. 
In the context of long term structural change to Nottingham’s economy – the move away from 
manufactures towards services – the case of bioscience in Nottingham presents something of a 
conundrum for local policy makers. On the face of it, the emergence of a bioscience cluster 
conveys a message of hope in demonstrating that it is indeed possible for localities to adapt, 
applying the legacies of old manufacturing industry to new knowledge intensive opportunities. 
Considered from another perspective it also encapsulates the scale of the challenges inherent 
in these processes. The new bioscience cluster is a fraction of the size of clusters in the ‘golden 
triangle’, such as the biotechnology cluster at Cambridge and the mass employing 
pharmaceuticals manufacturing sector from which it has emerged. Hence Nottingham will need 
to foster more clusters in other sectors, if its economy as a whole is to attain the sunlit uplands 
of a positive post-industrial future. From where these will arise is by no means clear.  
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Endnotes
1 Alan Sillitoe’s 1958 classic tale of industrial life in Nottingham. 
 
2 While pharmaceutical companies utilized features of Silicon Valley’s industrial structure 
(i.e. the degree of vertical integration) highlighted by Saxenian (1996), they do not appear to 
have relied on features of the region’s culture. 
 
3 The English Regional Development Agencies (RDAs) were created under Tony Blair’s first 
Labour Government 1997-2001. The Regional Development Agencies Act 1998 established 
8 regional development agencies in England that came into being in April 1999 (The London 
Development Agency followed a year later). Each RDA had a statutory remit to “(a) further 
the economic development and the regeneration of its area; (b) to promote business 
efficiency, investment and competitiveness in its area, (c) to promote employment in its area, 
(d) to enhance the development and application of skills relevant to employment in its area, 
and (e) to contribute to the achievement of sustainable development in the United Kingdom 
where it is relevant to its area to do so.” 
 
4 The latest initiative intended to kick start the process of regeneration on the site was its 
inclusion in a newly designated Enterprise Zone (Leicester and Leicestershire Enterprise 
Partnership 2017). 
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Table 1 
UK-owned Pharmaceutical companies, 1982 
UK 
Ranking 
Company Pharmaceutical 
sales (£m) 
Pharmaceuticals 
% Total sales 
World 
ranking 
1. Glaxo 990.0 88.0% 18th 
2. ICI 839.0 7.0% 23rd 
3. Wellcome 837.0 80.0% 24th 
4. Beacham 782.0 31.3% 25th 
5.  Boots 399.0 16.0% 42nd 
6. Fisons 206.0 36.0% 66th 
Source: Owen (1999) 
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Table 2 
Mergers and acquisitions in pharmaceuticals, 1989-2000 
Year Companies Countries 
1989 Dow/Marion US/US 
 Bristol-Myers/Squibb US/US 
 SmithKline/Beecham US/UK 
1990 Rhône-Poulenc/Rorer France/US 
 Roche/Genentech Switzerland/US 
1994 SmithKline Beecham/Sterling Health UK/US 
 BASF/Boots Germany/UK 
 American Home Products/ American Cynamid US/US 
 El Sanofi/Sterling Drug France/US 
 Roche/Syntex Switzerland/US 
1995 Glaxo/Wellcome UK/UK 
 Hoescht/Marion Merrell Dow Germany/US 
 Pharmacia/Upjohn Sweden/US 
 Rhône-Poulenc/Fisons France/UK 
1996 Ciba-Geigy/Sandoz Switzerland/Switzerland 
1997 Roche/Boehringer Switzerland/Germany 
1999 Hoescht/ Rhône-Poulenc Germany/France 
 Astra/Zeneca Sweden/UK 
2000 Glaxo Wellcome/SmithKline Beecham UK/UK 
 Pfizer/Warner-Lambert US/US 
 
Source: Owen (1999) 
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Table 3 
Chronology of Manoplax development 
Year Month Action 
1979 July Synthesis of BTS49465 
1980 March Animal tests start 
1982 September Tested on volunteers 
1983 October Clinical trial certificate 
1983 November Used in heart failures 
1984 December Approval inquiry starts 
1985 May UK Phase 2 dosage trials 
1990 July Phase 3 safety trials 
1991 October US heart panel approval 
1992 August License granted in UK 
1992 September Sent to UK doctors 
1992 December Licence granted in USA 
1993 March Launched in USA 
1993 April Warning on dosages 
1993 July Manoplax withdrawn 
 
Source: Hoskings (1993) 
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Table 4:  
Evidence of similar developments in other localities 
Incubator BioCity 
Nottingham 
BioPark Herts BioCity 
Scotland 
BioHub 
Manchester 
Location Nottingham Welwyn Motherwell Alderley Edge 
Parent firm BASF (ex 
Boots) 
Roche Merck AstraZeneca 
Source 
Industry 
Pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals 
Date est’d 2003 2006 2011 2013 
Principal 
institutional 
facilitators 
    
Development 
agency 
EMDA SEEDA Scottish 
Enterprise 
n/a 
Local authority Nottingham City 
Council 
Welwyn 
Hatfield 
Borough 
Council 
North 
Lanarkshire 
Council 
Cheshire East 
Council 
University Nottingham 
University/NTU 
Hertfordshire 
University 
Various in 
Glasgow and 
Edinburgh 
Manchester 
University 
NHS QMC    
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Figure 1: Towards an alternative path dependence model of local industrial evolution 
 
Source: (Martin 2010, 21) 
Figure 2 Simplified model of path creation loosely based on MSF 
 
 
 
